Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5719361 | 0.91 | L3MBTL1 (0.47) | LMNAALDH1A1TSHRNPSR1TP53 | |
| SCHEMBL5719592 | 0.84 | ALDH1A1 (0.76) | LMNAALDH1A1TSHRNPSR1POLB | |
| Trifluoroacetic Acid SCHEMBL5719039 | 0.84 | LMNA (0.55) | LMNAALDH1A1TSHRNPSR1POLB | |
| SCHEMBL5719876 | 0.82 | LMNA (0.45) | LMNAALDH1A1TSHRNPSR1POLB | |
| SCHEMBL5719498 | 0.79 | L3MBTL1 (0.49) | ALDH1A1TP53L3MBTL1 | |
| SCHEMBL5718793 | 0.78 | MEN1 (0.42) | LMNAALDH1A1TSHRNPSR1POLB | |
| SCHEMBL5719278 | 0.78 | MAOB (0.46) | LMNAALDH1A1TSHRNPSR1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL5719128 | 0.77 | LMNA (0.47) | LMNAALDH1A1TSHRNPSR1POLB | |
| SCHEMBL5719452 | 0.77 | LMNA (0.39) | LMNAALDH1A1TSHRNPSR1POLB | |
| SCHEMBL5718995 | 0.76 | DPP4 (0.44) | LMNAALDH1A1TSHRNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | LMNA 4075/4885ALDH1A1 112/4885TSHR 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.